rss
Br J Ophthalmol 2008;92:156-157 doi:10.1136/bjo.2007.118489
  • Letter
    • PostScript

Choroidal metastasis from gastrointestinal stromal tumour: a case report

  1. C M Gentile1,
  2. A A Lombardi2,
  3. J O Croxatto3
  1. 1
    Ocular Oncology, Hospital Italiano, Buenos Aires, Argentina
  2. 2
    Clinical and Surgical Retina, Hospital Italiano, Buenos Aires, Argentina
  3. 3
    Ocular Oncology, Hospital Italiano, Buenos Aires, Argentina
  1. C Gentile, Ocular Oncology Unit, Department of Ophthalmology, Hospital Italiano Buenos Aires, Gascón 450, Ciudad de Buenos Aires 1181, Argentina; carolina.gentile{at}hospitalitaliano.org.ar
  • Accepted 1 April 2007

Metastatic disease is the most frequent intraocular malignancy in adults. The most common sites of origin are breast and lung. The vast majority of metastatic intraocular tumours are carcinomas, and rarely neuroendocrine tumours and sarcomas. Gastrointestinal stromal tumours (GIST) constitute a distinct group of gastrointestinal tumours arising from the interstitial cells of Cajal, regulators of peristalsis. The development of imatinib mesylate, a receptor tyrosine kinase inhibitor, has made a major impact on the management of advanced GISTs. We report the case of a patient with choroidal and systemic disease from a GIST, who underwent therapy with imatinib. An accurate diagnosis is required since therapy may differ from the most common metastatic carcinomas.

Case report

A …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.